Immuneering Corporation

Healthcare · Biotechnology · United States

Last price 4.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.08M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica...